Back to Search
Start Over
Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells.
- Source :
-
Leukemia [Leukemia] 2009 Aug; Vol. 23 (8), pp. 1500-6. Date of Electronic Publication: 2009 Apr 02. - Publication Year :
- 2009
-
Abstract
- Once cleaved by caspases, the Lyn tyrosine kinase (LynDeltaN) is relocalized from the plasma membrane to the cytoplasm of apoptotic cells, but the function of such a cleavage is incompletely understood. We evaluated the effect of LynDeltaN overexpression on imatinib sensitivity of the chronic myelogenous leukemia (CML) cell line K562. Therefore, we generated stable cells that express plasmids encoding LynDeltaN or its catalytically inactive counterpart LynDeltaNKD. We established that Lyn is cleaved in imatinib-treated parental K562 cells in a caspase-dependent manner. Lyn cleavage also occurred following BCR-ABL silencing by specific short hairpin RNA (sh-RNA). Imatinib-induced apoptosis was abrogated in LynDeltaN-overexpressing cells, but not in cells overexpressing its inactive counterpart. Conversely, the overexpression of LynDeltaN failed to affect the differentiation of K562 cells. Importantly, the protective effect of LynDeltaN was suppressed by two inhibitors of Lyn activity. LynDeltaN also inhibits imatinib-mediated caspase-3 activation in the small proportion of nilotinib-resistant K562 cells overexpressing Lyn that can engage an apoptotic program upon imatinib stimulation. Finally, Lyn knockdown by sh-RNA altered neither imatinib-mediated apoptosis nor differentiation. Taken together, our data show that the caspase-cleaved form of Lyn exerts a negative feedback on imatinib-mediated CML cell apoptosis that is entirely dependent on its kinase activity and likely on the BCR-ABL pathway.
- Subjects :
- Antineoplastic Agents pharmacology
Benzamides
Caspase 9 genetics
Caspase Inhibitors
Enzyme Activation
Erythropoiesis drug effects
Fusion Proteins, bcr-abl antagonists & inhibitors
Fusion Proteins, bcr-abl physiology
Humans
Imatinib Mesylate
Indoles pharmacology
K562 Cells drug effects
K562 Cells enzymology
K562 Cells pathology
Leukemia, Myelogenous, Chronic, BCR-ABL Positive pathology
Neoplasm Proteins antagonists & inhibitors
Neoplasm Proteins chemistry
Neoplasm Proteins genetics
Protein Kinase Inhibitors pharmacology
Pyrimidines pharmacology
RNA Interference
RNA, Small Interfering pharmacology
Recombinant Fusion Proteins physiology
Signal Transduction drug effects
Structure-Activity Relationship
Sulfonamides pharmacology
src-Family Kinases antagonists & inhibitors
src-Family Kinases chemistry
src-Family Kinases genetics
Antineoplastic Agents antagonists & inhibitors
Apoptosis drug effects
Caspase 3 metabolism
Caspase 9 metabolism
Leukemia, Myelogenous, Chronic, BCR-ABL Positive enzymology
Neoplasm Proteins physiology
Piperazines antagonists & inhibitors
Protein Kinase Inhibitors antagonists & inhibitors
Pyrimidines antagonists & inhibitors
src-Family Kinases physiology
Subjects
Details
- Language :
- English
- ISSN :
- 1476-5551
- Volume :
- 23
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Leukemia
- Publication Type :
- Academic Journal
- Accession number :
- 19340007
- Full Text :
- https://doi.org/10.1038/leu.2009.60